Business
Akebia Therapeutics Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences: \n\n \n \n \n \n \n \n\n \nPiper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 29 – December 2, 2021 John Butler will participate in a virtual fireside chat, which will be available on the conference site prior to the virtual event. \n4th Annual Evercore ISI HealthCONx Conference November 30 - December 2, 2021John Butler will participate in a virtual fireside chat, which will be presented on Tuesday, November 30 at 4:45 on the conference site. \nWhere applicable, webcasts of Akebia's fireside chats will be made available on the Investors section of the Company's website at https://ir.akebia.com.\nAbout Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.\nAkebia Therapeutics ContactMercedes [email protected] \n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-participation-in-upcoming-investor-conferences-301431123.html\nSOURCE Akebia Therapeutics","length":3938,"tagName":"div"}]